《The 2021 annual drug review report 》shows that the breakthrough treatment drug procedure, conditional approval procedure,priority review and approval procedure, and special approval procedure. Four "fast channels 'help accelerate drug research and development and marketing.

In 2021, anumber of drugs in urgent need will enter the "fast track". 53 registration applications (41 varieties) were included in the breakthrough treatment drug program, covering diseases caused by covid-19 infection, non-small cell lung cancer,ovarian cancer and other indications. 115 registration applications (69 varieties) were included in the priority review and approval procedures, including 41 drugs that met the conditions approved, and 34 new varieties, dosage forms and specifications of children's drugs that met the physiological characteristics of children. In addition, 81 registration applications that were included in the special approval procedures were concluded throughout the year, all of which were covid-19 vaccine and therapeutic drugs.